
|Articles|March 1, 2001
- Pharmaceutical Executive-03-01-2001
- Volume 0
- Issue 0
Research: New Horizons
Author(s)Kevin Gopal
London, UK-Changes to the law on human embryo research could herald a new era for UK biotech research. The government feared its proposals to allow the cloning of embryos as sources for stem cells for research would be thrown out by the House of Lords-where a powerful body of opinion holds that they represent a slippery slope toward reproductive cloning-but the proposals passed by a surprisingly large majority.
Advertisement
Articles in this issue
over 25 years ago
Earnings: Tough Times Aheadover 25 years ago
Outbreak: Anthrax Alarmover 25 years ago
Patents: China on the Genome Mapover 25 years ago
Privacy, Pediatrics, and Policyover 25 years ago
Lilly's International Familyover 25 years ago
Update: Punishment and Reprieveover 25 years ago
Shortage: Vaccine Worriesover 25 years ago
Gateway to Japanover 25 years ago
SurroundedAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
Trump Administration Preparing New Round of Medicaid Drug-Pricing Deals: Report
2
M&A Roundup: DualityBio & Genentech Enter Partnership to Develop Next Generation ADC’s, Teva Bids to Acquire Igalmi from BioXcel
3
Study Shows Link Between Zepbound and Lower Healthcare Costs in Adults Aged 55 and Up with Obesity: Report
4
Pharmaceutical Executive Daily: DualityBio and Teva Strike Major Biopharma Deals
5




